As of May 23, 2025, Myovant Sciences Ltd (MYOV) reports a ROA (Return on Assets) of -39.61%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Myovant Sciences Ltd's ROA (Return on Assets)
Over recent years, Myovant Sciences Ltd's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2022-03-31 | -39.61% |
| 2021-03-31 | -35.19% |
| 2020-03-31 | -272.89% |
| 2019-03-31 | -158.12% |
| 2018-03-31 | -120.29% |
This gradual decrease highlights how Myovant Sciences Ltd manages its efficiency in using assets to generate earnings over time.
Comparing Myovant Sciences Ltd's ROA (Return on Assets) to Peers
To better understand Myovant Sciences Ltd's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Myovant Sciences Ltd (MYOV) | -39.61% |
| Krystal Biotech Inc (KRYS) | 8.44% |
| Abcam PLC (ABC.L) | 1.74% |
| Genus PLC (GNS.L) | 0.77% |
| Seres Therapeutics Inc (MCRB) | 0.10% |
| Immunocore Holdings PLC (IMCR) | -5.06% |
Compared to its competitors, Myovant Sciences Ltd's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.